molecules of the month


FR-targeted DNA crosslinking agent conjugate

activity in xenograft w/ once weekly dosing

from conjugation of FR-ligand and PBD dimer

Sci. Rep., Jul. 29, 2020

Endocyte, West Lafayette, IN / Novartis

Structure of EC2629, a folate receptor (FR)-targeted small molecule drug conjugate
1 min read

EC2629 is a folate receptor (FR)-targeted small molecule drug conjugate with a folate receptor-targeting moiety, a pyrrolobenzodiazepine (PBD) DNA-crosslinking warhead, and a linker. Similar to antibody-drug conjugates, this small molecule conjugate is intended to maintain the activity of the potent PBD warhead while minimizing systemic toxicity by targeting tumor cells expressing the folate receptor. I think the small molecule drug conjugate concept is an interesting one, though previous clinically tested molecules like vintafolide haven’t shown much promise yet. There’s probably a strong use case for this modality somewhere to be discovered!

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: